Eosinophilic Gastroenteritis Market

Key Highlights

• As per DelveInsight, the Eosinophilic Gastroenteritis Market is expected to expand at a healthy growth rate during the forecast period (2023-2032), owing to the launch of new therapies in the market and the rise in the number of cases. 
• Several major pharma and biotech companies such as Allakos, and AstraZeneca, among others, are actively working in the Eosinophilic Gastroenteritis Market. 

Download the Sample PDF to Get More Insight @ Eosinophilic Gastroenteritis Market

DelveInsight's "Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Eosinophilic Gastroenteritis, historical and forecasted epidemiology as well as the Eosinophilic Gastroenteritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Eosinophilic Gastroenteritis market report provides current treatment practices, emerging drugs, Eosinophilic Gastroenteritis market share of the individual therapies, current and forecasted Eosinophilic Gastroenteritis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Eosinophilic Gastroenteritis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Eosinophilic Gastroenteritis market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Eosinophilic Gastroenteritis Overview

Eosinophilic Gastroenteritis is a rare digestive disease characterized by the triad of eosinophilic infiltration of segments of the gastrointestinal tract, abnormalities of gastrointestinal function (varying from dyspepsia and obstruction to diarrhea and ascites), and exclusion of other diseases with peripheral eosinophilia.

Eosinophilic Gastroenteritis Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Eosinophilic Gastroenteritis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Eosinophilic Gastroenteritis market report thoroughly understands Eosinophilic Gastroenteritis symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Eosinophilic Gastroenteritis treatment algorithms and treatment guidelines for Eosinophilic Gastroenteritis symptoms in the US, Europe, and Japan.

The management options for this disorder include both dietary and pharmacological approaches, with corticosteroids being the mainstay of therapy and highly effective. Although spontaneous remission is reported in around 30–40% of EGE cases, most patients require ongoing treatment.

An alternative therapeutic armamentarium includes mast-cell stabilizers, leukotriene antagonists, antihistamines, immunomodulators, and biological agents.

However, the unmet needs, including lack of curative therapies, need for therapies with minimal toxicity profile, high clinical and economic burden, and high cost of approved therapies, are driving opportunities in the market.

Eosinophilic Gastroenteritis Epidemiology

The Eosinophilic Gastroenteritis epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

Key Findings

The total prevalent cases of Eosinophilic Gastroenteritis is increased by 7MM during the study period, i.e., 2020-2034.

The disease epidemiology covered in the report provides historical as well as forecasted Eosinophilic Gastroenteritis symptoms epidemiology segmented as the Prevalence of Eosinophilic Gastroenteritis, Gender-specific cases of Eosinophilic Gastroenteritis, and Age-specific Cases of Eosinophilic Gastroenteritis. The report includes the prevalent scenario of Eosinophilic Gastroenteritis symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019-2032.

Country-wise Eosinophilic Gastroenteritis Epidemiology

The epidemiology segment also provides the Eosinophilic Gastroenteritis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total number of prevalent cases of Eosinophilic Gastroenteritis associated in 7MM countries was 58,560 in 2020.

Get detailed insights into the historical as well as forecasted epidemiology trends in the 7MM, at: Eosinophilic Gastroenteritis (EGE) Epidemiology Forecast

Eosinophilic Gastroenteritis Drug Chapters

The Eosinophilic Gastroenteritis report’s drug chapter segment encloses the detailed analysis of Eosinophilic Gastroenteritis early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Eosinophilic Gastroenteritis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Eosinophilic Gastroenteritis Emerging Drug

Lirentelimab: Allakos

Lirentelimab/AK002 is an investigational, non-fucosylated IgG1 monoclonal antibody targeting Siglec-8. Lirentelimab blocks multiple inflammatory pathways by targeting Siglec-8, an inhibitory receptor. The binding to Siglec-8 induces inhibition of mast cells, apoptosis of tissue eosinophils, and depletion of blood eosinophils by antibody-dependent cellular cytotoxicity (ADCC). Currently, the drug Lirentelimab is in Phase III clinical trial for eosinophilic gastroenteritis disease.

It has demonstrated positive clinical activity in diseases that are driven by mast cells, and eosinophils (e.g., eosinophilic esophagitis, eosinophilic gastritis, and/or eosinophilic duodenitis) and diseases are believed to be driven by mast cells only (e.g., chronic urticaria, indolent systemic mastocytosis). Clinical and preclinical results demonstrate that lirentelimab broadly inhibits mast cells and rapidly depletes eosinophils.

Benralizumab: AstraZeneca

Benralizumab (Fasenra) is a humanized fucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM. The IL-5 receptor is expressed on the surface of eosinophils and basophils. In an in vitro setting, the absence of fucose in the Fc domain of benralizumab facilitates binding (45.5 nM) to FcɣRIII receptors on immune effector cells, such as natural killer (NK) cells, leading to apoptosis of eosinophils and basophils through antibody-dependent cell-mediated cytotoxicity (ADCC). Benralizumab is currently approved under the brand name Fasenra as an add-on maintenance treatment of severe asthma in patients aged ≥12 years and with an eosinophilic phenotype.

Products detail in the report…

Eosinophilic Gastroenteritis Market Outlook

The report’s Eosinophilic Gastroenteritis market outlook helps to better understand the historic, current, and forecasted Eosinophilic Gastroenteritis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Eosinophilic Gastroenteritis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

According to DelveInsight, the Eosinophilic Gastroenteritis market in 7MM is expected to grow in the study period 2020-2034.

There are no medications that have been specifically approved by the Food and Drug Administration (FDA) of the United States for use in EGE. Fifty to seventy-five percent of patients with EGE have concomitant allergies or atopic disorders. Recognizing the food allergen and dietary restriction is an integral part of EG management. Different management strategies have been used for patients with EGE. The management options for this disorder include both dietary and pharmacological approaches, with corticosteroids being the mainstay of therapy and highly effective.

An alternative therapeutic armamentarium includes mast-cell stabilizers, leukotriene antagonists, antihistamines, immunomodulators, and biological agents.

Key Findings

This section includes a glimpse of the Eosinophilic Gastroenteritis market in 7MM.

Eosinophilic Gastroenteritis market size in the seven major markets was USD 74.7 million in 2020.

The United States Market Outlook

This section provides the total Eosinophilic Gastroenteritis market size and market size by therapies in the United States.

The United States accounts for the largest market size of Eosinophilic Gastroenteritis in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Eosinophilic Gastroenteritis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Eosinophilic Gastroenteritis Market Size by therapies in Japan are also mentioned.

Eosinophilic Gastroenteritis Drugs Uptake

This section focuses on the uptake of the potential Eosinophilic Gastroenteritis drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers the Eosinophilic Gastroenteritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Eosinophilic Gastroenteritis Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Eosinophilic Gastroenteritis key players involved in developing targeted therapeutics.

Major players include Allakos, AstraZeneca, and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Eosinophilic Gastroenteritis emerging therapies.

Reimbursement Scenario in Eosinophilic Gastroenteritis

Approaching reimbursement proactively can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

The high treatment costs, including chemo and other therapies, affect patients’ affordability and access to these treatment options. Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the drug price relative to the benefit it produces in treated patients.

The disease advocacy groups working in the area of Eosinophilic Gastroenteritis helps patients with medical billing, insurance coverage, and reimbursement issues. Also, financial assistance is available from both governments and pharmaceutical companies to help people who cannot afford the cost of their medications.

KOL- Views

To keep up with current Eosinophilic Gastroenteritis market trends, we take KOLs and SMEs ' opinion working in the Eosinophilic Gastroenteritis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Eosinophilic Gastroenteritis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Eosinophilic Gastroenteritis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Eosinophilic Gastroenteritis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Eosinophilic Gastroenteritis epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Eosinophilic Gastroenteritis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Eosinophilic Gastroenteritis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Eosinophilic Gastroenteritis market

Report Highlights

• In the coming years, the Eosinophilic Gastroenteritis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Eosinophilic Gastroenteritis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Eosinophilic Gastroenteritis. The launch of emerging therapies will significantly impact the Eosinophilic Gastroenteritis market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Eosinophilic Gastroenteritis
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Eosinophilic Gastroenteritis Market Report Insights

• Eosinophilic Gastroenteritis Patient Population
• Eosinophilic Gastroenteritis Therapeutic Approaches
• Eosinophilic Gastroenteritis Pipeline Analysis
• Eosinophilic Gastroenteritis Market Size and Trends
• Eosinophilic Gastroenteritis Market Opportunities
• Impact of Upcoming Eosinophilic Gastroenteritis Therapies

Eosinophilic Gastroenteritis Market Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Eosinophilic Gastroenteritis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Eosinophilic Gastroenteritis Market
• Eosinophilic Gastroenteritis Drugs Uptake

Eosinophilic Gastroenteritis Market Report Assessment

• Current Eosinophilic Gastroenteritis Treatment Practices
• Unmet Needs in the Eosinophilic Gastroenteritis Market
• Eosinophilic Gastroenteritis Pipeline Product Profiles
• Eosinophilic Gastroenteritis Market Attractiveness
• Eosinophilic Gastroenteritis Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Eosinophilic Gastroenteritis drug class share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Eosinophilic Gastroenteritis total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Eosinophilic Gastroenteritis market size during the forecast period (2020-2034)?
• At what CAGR, the Eosinophilic Gastroenteritis market is expected to grow by 7MM during the forecast period (2020-2034)?
• What would be the Eosinophilic Gastroenteritis market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Eosinophilic Gastroenteritis market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Eosinophilic Gastroenteritis?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Eosinophilic Gastroenteritis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Eosinophilic Gastroenteritis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Eosinophilic Gastroenteritis?
• Out of all 7MM countries, which country would have the highest prevalent population of Eosinophilic Gastroenteritis during the forecast period (2020-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current options for the Eosinophilic Gastroenteritis treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Eosinophilic Gastroenteritis in the USA, Europe, and Japan?
• What are the Eosinophilic Gastroenteritis marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Eosinophilic Gastroenteritis?
• How many therapies are in-development by each company for Eosinophilic Gastroenteritis treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Eosinophilic Gastroenteritis treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Eosinophilic Gastroenteritis therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Eosinophilic Gastroenteritis and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Eosinophilic Gastroenteritis?
• What are the global historical and forecasted market of Eosinophilic Gastroenteritis?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Eosinophilic Gastroenteritis market
• To understand the future market competition in the Eosinophilic Gastroenteritis market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Eosinophilic Gastroenteritis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Eosinophilic Gastroenteritis market
• To understand the future market competition in the Eosinophilic Gastroenteritis market